Cell therapy company apceth has appointed Ulrike Verzetnitsch in the newly created role of chief technical officer.
In the position, Verzetnitsch will lead apceth’s production facilities and operations and continue the expansion of its fee-for-service GMP manufacturing business.
Commenting on the appointment, Christine Guenther, CEO of apceth, said: “apceth has recently started phase II of the world’s first clinical trial with genetically modified mesenchymal stem cells in cancer indications and is simultaneously increasing its manufacturing capacity and capabilities as a CMO. It is therefore a very exciting time for us to welcome Ulrike to the team.
“Her experience will complement our management team and help drive apceth forward.”
She joins from Takeda, where she was head of the production unit based in Singen, Germany. Prior to that, Verzetnitsch held the role of director of production at Baxter, where she focused on strategic tasks in the final container operation of vaccines and plasma-based and recombinant products.
As part of her role, she gained experience in the manufacturing of products for worldwide distribution in compliance with the FDA, EMEA, Japanese and other guidelines.